Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Larson

Showing results (181-190 of 208) with videos related to

Pageof 21
Sort By:
Leukemia|March 21, 2003
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002P M Navolanic, C-H Pui, R A Larson, et al.
Leukemia|December 14, 2011
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseF J Giles, H M Kantarjian, P D le Coutre, et al.
Blood|August 26, 1998
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111R A Larson, R K Dodge, C A Linker, et al.
Leukemia|March 14, 2009
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaA Hochhaus, S G O'Brien, F Guilhot, et al.
Bone Marrow Transplantation|June 18, 2013
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromesF Locke, R Agarwal, R Kunnavakkam, et al.
Leukemia|June 16, 2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upR A Larson, A Hochhaus, T P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndromeKoen van Besien, A Artz, S Smith, et al.
Cancer Research|October 5, 2001
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B studyS P Whitman, K J Archer, L Feng, et al.
Leukemia|July 17, 1998
Establishment and characterization of a megakaryoblast cell line with amplification of MLLR J Allen, S D Smith, R L Moldwin, et al.
Annals of Hematology|May 6, 2004
G3139, a BCL-2 antisense oligo-nucleotide, in AMLG Marcucci, W Stock, G Dai, et al.
Pageof 21

Showing results (181-190 of 208) with videos related to

Sort By:
Pageof 21
Leukemia|March 21, 2003
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002P M Navolanic, C-H Pui, R A Larson, et al.
Leukemia|December 14, 2011
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseF J Giles, H M Kantarjian, P D le Coutre, et al.
Blood|August 26, 1998
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111R A Larson, R K Dodge, C A Linker, et al.
Leukemia|March 14, 2009
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaA Hochhaus, S G O'Brien, F Guilhot, et al.
Bone Marrow Transplantation|June 18, 2013
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromesF Locke, R Agarwal, R Kunnavakkam, et al.
Leukemia|June 16, 2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upR A Larson, A Hochhaus, T P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndromeKoen van Besien, A Artz, S Smith, et al.
Cancer Research|October 5, 2001
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B studyS P Whitman, K J Archer, L Feng, et al.
Leukemia|July 17, 1998
Establishment and characterization of a megakaryoblast cell line with amplification of MLLR J Allen, S D Smith, R L Moldwin, et al.
Annals of Hematology|May 6, 2004
G3139, a BCL-2 antisense oligo-nucleotide, in AMLG Marcucci, W Stock, G Dai, et al.
Pageof 21